Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
Revenue of Intercept Pharmaceuticals, Inc. (ICPT)
Revenue in 2022 (TTM): $285.71 M
According to Intercept Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $285.71 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Intercept Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2022 | $285.71 M | $284.73 M | $-61,695,000 | $-174,858,000 | $115.17 M |
| 2021 | $363.47 M | $360.37 M | $-53,604,000 | $-91,426,000 | $-145,022,000 |
| 2020 | $312.69 M | $307.37 M | $-212,196,000 | $-274,880,000 | $-324,230,000 |
| 2019 | $252 M | $247.79 M | $-303,537,000 | $-344,681,000 | $-391,052,000 |
| 2018 | $179.8 M | $177.29 M | $-278,719,000 | $-309,242,000 | $-309,242,000 |
| 2017 | $130.96 M | $129.59 M | $-331,096,000 | $-360,367,000 | $-360,367,000 |
| 2016 | $24.95 M | $24.95 M | $-398,634,000 | $-412,830,000 | $-412,830,000 |
| 2015 | $2.78 M | $2.78 M | $-226,429,000 | $-226,429,000 | $-226,429,000 |
| 2014 | $1.74 M | $1.74 M | $57.66 M | $-283,226,000 | $-283,226,000 |
| 2013 | $1.62 M | $1.62 M | $-10,904,970 | $-67,792,410 | $-67,792,410 |
| 2012 | $2.45 M | $2.45 M | $5.71 M | $-43,644,000 | $-43,644,000 |
| 2011 | $1.81 M | $1.81 M | $-14,464,679 | $-13,830,454 | $-12,737,654 |
| 2010 | $ | $ | $-16,057,231 | $-15,087,223 | $-15,087,223 |